Biotinylated Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein
Catalog No: P53WT-HB001
- Species
- Human
- Expression System
- E. coli
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and HMTEVVRRC peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &HMTEVVRRC).
Product Details
- Molecular Aliases
- MHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53
- Protein Length
- Gly25-Thr305
- Expression System
- E. coli
- Theoretical Molecular Weight
- The protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
- State
- Liquid
- Storage Conditions
- Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Biotinylated Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer, His-Avi tag at 1μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 14.8ng/ml determined by ELISA.
Background
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.
References
- (1)Donnellan Z, Bossi G, Harper J, et al. ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing[J]. Journal for ImmunoTherapy of Cancer, 2015, 3(Suppl 2):P299.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.